Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS0QEP)

Drug Name
SB 206553 Drug Info
Synonyms
SB 206553; 158942-04-2; SB-206553; Tocris-1661; CHEMBL297784; CHEBI:8977; UNII-AL4387525T; AL4387525T; SB-206,553; 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide; SB-206553 hydrochloride hydrate; SB206553; Lopac-S-180; AC1L1JQU; AC1Q5NRE; Lopac0_001163; GTPL189; SCHEMBL1459242; ZINC5994; DTXSID9043984; CTK8H1211; BDBM50060417; pyrrolo[2,3-f]indole-1(2h)-carboxamide, 3,5-dihydro-5-methyl-n-3-pyridinyl-; AKOS027381420; 5-Methyl-N-(3-pyridinyl)-3,5-dihydropyrrolo[2,3-f]indole-1(2H)-carboxamide; CCG-205237
Cross-matching ID
PubChem CID
5163
ChEBI ID
CHEBI:8977
CAS Number
CAS 158942-04-2
TTD Drug ID
DMS0QEP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Triflupromazine DMKFQJP Nausea MD90 Approved [4]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [5]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [6]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [7]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [8]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [9]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [9]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [9]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [2]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [2]
Fluoxetine DM3PD2C Bipolar depression Approved [2]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [10]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [11]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [12]
Testosterone DM7HUNW Hot flushes GA30 Approved [13]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [14]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [15]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Gene/Protein Processing [2]

References

1 Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze. Braz J Med Biol Res. 2001 May;34(5):675-82.
2 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
3 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
4 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
5 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
6 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
7 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
8 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
9 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
10 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
11 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
12 Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
13 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
14 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
15 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
16 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.